medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer

대한대장항문학회지 2010년 26권 4호 p.287 ~ 292
 ( Yun Jung-A ) - 성균관대학교 의과대학 삼성서울병원 외과

김희철 ( Kim Hee-Cheol ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
 ( Son Hyun-Sook ) - 삼성서울병원 간호부
 ( Kim Hyoung-Ran ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
윤해란 ( Yun Hae-Ran ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
조용범 ( Cho Yong-Beom ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
윤성현 ( Yun Seong-Hyeon ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
이우용 ( Lee Woo-Yong ) - 성균관대학교 의과대학 삼성서울병원 외과학교실
전호경 ( Chun Ho-Kyung ) - 성균관대학교 의과대학 삼성서울병원 외과학교실

Abstract


Purpose: Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initiated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are unclear. The present study sought to clarify treatment outcomes in such patients.

Methods: The study included 173 patients who had been diagnosed with stage II or III colon cancer according to the pathologic report after radical surgery at Samsung Medical Center from May 2005 to June 2007 and who had received capecitabine as adjuvant therapy. The patients were divided into groups according to whether the dose was reduced (I, dose maintenance; II, dose reduction) or stopped (A, cycle completion; B, cycle cessation). Recurrence and disease-free survival rates between the two groups each were analyzed.

Results: Of the 173 patients, 128 (74.6%) experienced complications, most frequently hand-foot syndrome (n = 114). Reduction (n = 35) or cessation (n = 18) of medication was most commonly due to complications. Concerning reduced dosage, both groups displayed no statistically significant differences in recurrence rate and 3-year disease-free survival rate. Concerning discontinued medication use, the cycle completion group showed an improved recurrence rate (P = 0.048) and 3-year disease-free survival rate (P = 0.028).

Conclusion: The results demonstrate that maintaining compliance with capecitabine as an adjuvant treatment for colon cancer to preventing complications positively affects patient prognosis.

키워드

Colon cancer; Capecitabine; Dose; Cycle; Disease-free survival
원문 및 링크아웃 정보
  
등재저널 정보
KCI
KoreaMed
KAMS